私の芝居体験


�V
Further clinical trials are now underway employing MABs directed against the accessory molecules, CD4 and CD54, which have been found to be essential for the interactions between T cells and histocompatibility antigens. Based on the exciting observation of tolerance induction by such agents in preclinical models, one anticipates that these agents may play an important role in future clinical protocols.
�W
The clinical applicability of the anti-CD25 reagents remains unclear. Although some studies have suggested immunosuppressive efficacy, the observations have been inconsistent. As a result, some efforts are now being directed toward the development of hybrid reagents that can deliver to selected targets highly toxic molecules conjugated to the MAB. In view of the difficulties still encountered with such immunotoxin therapy in oncology, it seems unlikely that this approach will become useful for allograft recipients in the immediate future.
�X
One of the more promising additions to MAB technology is the recombinant DNA technology used to humanize murine or rat preparations. With these methods, novel antibody molecules that retain only short sequences from the rodent variable region can now be constructed. Preclinical trials suggest that these designer molecules are less immunogenic and that they can more effectively recruit, in vivo, the immune mechanisms necessary for lasting suppression. Clearly, the development of these new molecular agents, more effectively directed to specific cellular targets, will play an increasingly important role in future clinical protocols and perhaps finally provide a maens to achieve long-term tolerance.